Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Morepen Laboratories Ltd. Share Price
Day's Range
Day's Range
Low
₹42.51
High
₹44.79
Price Summary
| Previous Close | ₹42.91 |
|---|---|
| Day's Range | ₹42.51 - ₹44.79 |
| Open | ₹43.19 |
| 52 Week Range | ₹33.05 - ₹70.50 |
| Volume | 39,91,650 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 1,735.99 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.47 |
| Price/Earning (TTM) | 23.64 |
| TTM EPS (₹) | 1.81 |
| P/E Ratio | 22.21 |
| Book Value(₹) | 1.92 |
| PAT Margin (%) | 6.51 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 15.48 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 4032.55 | 16904.32 |
| Expenses | N/A | N/A |
| PBT | 303.78 | 1349.55 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 226.86 | 961.59 |
About Morepen Laboratories Ltd.
| Founded | 1984 |
|---|---|
| Managing Director | Sushil Suri |
| NSE Symbol | MOREPENLAB |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,42,725.29 | 1,845.20 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,82,775.12 | 6,905.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,51,764.01 | 4,494.00 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,20,200.38 | 8,361.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,13,007.26 | 1,398.95 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,09,098.01 | 1,308.60 | 1,148.40 - 1,148.40 |
| Zydus Lifesciences Ltd. | 1,04,542.68 | 1,038.95 | 835.50 - 835.50 |
| Lupin Ltd. | 1,04,222.36 | 2,279.50 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 1,02,422.13 | 2,479.00 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 99,587.17 | 1,023.25 | 903.00 - 903.00 |
No Records Found
Latest News
Morepen Laboratories informs about press release
Concord Biotech informs about board meeting
Concord Biotech has informed that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026, inter alia, to consider and approve the audited Standalone and Consolidated Financial Results for the fourth quarter and financial year ended March 31, 2026 along with audit report thereon and subject to approval of shareholders at the ensuing Annual General Meeting, to recommend final dividend on equity shares of the Company.
The above information is a part of company’s filings submitted to BSE.
Shilpa Medicare - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 2011.10 | 1262.10 | 59.35 | 5970.30 | 4774.10 | 25.06 | 5970.30 | 4774.10 | 25.06 |
| Other Income | 68.90 | 106.40 | -35.24 | 381.40 | 696.70 | -45.26 | 381.40 | 696.70 | -45.26 |
| PBIDT | 666.80 | 486.60 | 37.03 | 1938.60 | 2058.00 | -5.80 | 1938.60 | 2058.00 | -5.80 |
| Interest | 26.20 | 19.10 | 37.17 | 100.40 | 58.70 | 71.04 | 100.40 | 58.70 | 71.04 |
| PBDT | 924.30 | 24.30 | 3703.70 | 2032.40 | 1541.90 | 31.81 | 2032.40 | 1541.90 | 31.81 |
| Depreciation | 144.10 | 123.40 | 16.77 | 551.10 | 488.60 | 12.79 | 551.10 | 488.60 | 12.79 |
| PBT | 780.20 | -99.10 | -887.29 | 1481.30 | 1053.30 | 40.63 | 1481.30 | 1053.30 | 40.63 |
| TAX | 70.60 | -42.80 | -264.95 | 151.60 | 374.40 | -59.51 | 151.60 | 374.40 | -59.51 |
| Deferred Tax | 13.80 | -59.40 | -123.23 | 76.60 | -96.40 | -179.46 | 76.60 | -96.40 | -179.46 |
| PAT | 709.60 | -56.30 | -1360.39 | 1329.70 | 678.90 | 95.86 | 1329.70 | 678.90 | 95.86 |
| Equity | 195.60 | 97.80 | 100.00 | 195.60 | 97.80 | 100.00 | 195.60 | 97.80 | 100.00 |
| PBIDTM(%) | 33.16 | 38.55 | -14.00 | 32.47 | 43.11 | -24.68 | 32.47 | 43.11 | -24.68 |
Sun Pharma Inds. - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 49238.80 | 71794.50 | -31.42 | 207546.40 | 229774.00 | -9.67 | 207546.40 | 229774.00 | -9.67 |
| Other Income | 629.30 | 1321.30 | -52.37 | 4193.30 | 3791.40 | 10.60 | 4193.30 | 3791.40 | 10.60 |
| PBIDT | 13919.00 | 31915.80 | -56.39 | 66000.20 | 72168.40 | -8.55 | 66000.20 | 72168.40 | -8.55 |
| Interest | 2169.20 | 2323.80 | -6.65 | 9478.40 | 9538.90 | -0.63 | 9478.40 | 9538.90 | -0.63 |
| PBDT | 11749.80 | 29592.00 | -60.29 | 51058.40 | 62629.50 | -18.48 | 51058.40 | 62629.50 | -18.48 |
| Depreciation | 3259.70 | 3054.40 | 6.72 | 13117.20 | 12867.40 | 1.94 | 13117.20 | 12867.40 | 1.94 |
| PBT | 8490.10 | 26537.60 | -68.01 | 37941.20 | 49762.10 | -23.75 | 37941.20 | 49762.10 | -23.75 |
| TAX | 2403.10 | 6117.90 | -60.72 | 11707.00 | 7481.30 | 56.48 | 11707.00 | 7481.30 | 56.48 |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PAT | 6087.00 | 20419.70 | -70.19 | 26234.20 | 42280.80 | -37.95 | 26234.20 | 42280.80 | -37.95 |
| Equity | 2399.30 | 2399.30 | 0.00 | 2399.30 | 2399.30 | 0.00 | 2399.30 | 2399.30 | 0.00 |
| PBIDTM(%) | 28.27 | 44.45 | -36.41 | 31.80 | 31.41 | 1.25 | 31.80 | 31.41 | 1.25 |
Torrent Pharma - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 27350.00 | 24330.00 | 12.41 | 107120.00 | 96820.00 | 10.64 | 107120.00 | 96820.00 | 10.64 |
| Other Income | 580.00 | 150.00 | 286.67 | 180.00 | 320.00 | -43.75 | 180.00 | 320.00 | -43.75 |
| PBIDT | 10610.00 | 8830.00 | 20.16 | 40720.00 | 36070.00 | 12.89 | 40720.00 | 36070.00 | 12.89 |
| Interest | 2250.00 | 470.00 | 378.72 | 3410.00 | 2130.00 | 60.09 | 3410.00 | 2130.00 | 60.09 |
| PBDT | 7890.00 | 8120.00 | -2.83 | 36610.00 | 33700.00 | 8.64 | 36610.00 | 33700.00 | 8.64 |
| Depreciation | 1970.00 | 1900.00 | 3.68 | 7640.00 | 7600.00 | 0.53 | 7640.00 | 7600.00 | 0.53 |
| PBT | 5920.00 | 6220.00 | -4.82 | 28970.00 | 26100.00 | 11.00 | 28970.00 | 26100.00 | 11.00 |
| TAX | 1250.00 | 1480.00 | -15.54 | 7050.00 | 7220.00 | -2.35 | 7050.00 | 7220.00 | -2.35 |
| Deferred Tax | 530.00 | -120.00 | -541.67 | -150.00 | 1810.00 | -108.29 | -150.00 | 1810.00 | -108.29 |
| PAT | 4670.00 | 4740.00 | -1.48 | 21920.00 | 18880.00 | 16.10 | 21920.00 | 18880.00 | 16.10 |
| Equity | 1692.30 | 1692.30 | 0.00 | 1692.30 | 1692.30 | 0.00 | 1692.30 | 1692.30 | 0.00 |
| PBIDTM(%) | 38.79 | 36.29 | 6.89 | 38.01 | 37.25 | 2.04 | 38.01 | 37.25 | 2.04 |
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Morepen Laboratories Ltd. is ₹42.91 as of 2026-05-22.
The market capitalisation of Morepen Laboratories Ltd. is ₹2,350.72 as of 2026-05-22.
The 1-year return of Morepen Laboratories Ltd. is 0.00% as of 2026-05-22.
The P/E ratio of Morepen Laboratories Ltd. is 22.21 as of 2026-05-23.
The 52-week high and low of Morepen Laboratories Ltd. are ₹70.50 and ₹33.05, respectively, as of 2026-05-22.
People Also Ask
Morepen Laboratories Ltd. offers a broad healthcare portfolio that includes Active Pharmaceutical Ingredients (APIs) such as antihistamines and statins, as well as known branded OTC products like Burnol. Their offerings also extend to a diagnostics division that provides home-health devices, including digital glucose monitors and blood pressure monitors.
Morepen Laboratories Ltd. collaborates with pharmaceutical companies through the supply of Active Pharmaceutical Ingredients (APIs) and contract manufacturing services. The company also supplies diagnostic medical devices and point-of-care testing solutions that are used by hospitals, clinics and other healthcare providers for patient monitoring and diagnostic purposes.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
